{"nctId":"NCT01095835","briefTitle":"A Study of Pegylated Interferon Alfa-2a and Lamivudine in Patients With HBeAg-Negative Chronic Hepatitis B Virus (HBV)","startDateStruct":{"date":"2005-02"},"conditions":["Hepatitis B, Chronic"],"count":131,"armGroups":[{"label":"PEG-IFN48","type":"EXPERIMENTAL","interventionNames":["Drug: Pegylated interferon (PEG-IFN) alfa-2a, 180 mcg"]},{"label":"PEG-IFN96","type":"EXPERIMENTAL","interventionNames":["Drug: Pegylated interferon (PEG-IFN) alfa-2a, 180 mcg","Drug: Pegylated interferon (PEG-IFN) alfa-2a, 135 mcg"]},{"label":"PEG-IFN+LAM96","type":"EXPERIMENTAL","interventionNames":["Drug: Pegylated interferon (PEG-IFN) alfa-2a, 180 mcg","Drug: Pegylated interferon (PEG-IFN) alfa-2a, 135 mcg","Drug: Lamivudine (LAM)"]}],"interventions":[{"name":"Pegylated interferon (PEG-IFN) alfa-2a, 180 mcg","otherNames":["Pegasys®"]},{"name":"Pegylated interferon (PEG-IFN) alfa-2a, 135 mcg","otherNames":["Pegasys®"]},{"name":"Lamivudine (LAM)","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* adults 18-70 years of age;\n* HBeAg-negative chronic hepatitis B for \\>/=6 months;\n* liver disease consistent with chronic hepatitis B.\n\nExclusion Criteria:\n\n* interferon-based, systemic anti-HBV, antiviral, anti-neoplastic, or immunomodulatory therapy \\</=12 months before first dose of study drug;\n* non-responders to previous interferon therapy;\n* co-infection with hepatitis A, C or D, or with human immunodeficiency virus (HIV);\n* hepatocellular cancer;\n* compensated (Child A, score 6) or decompensated liver disease (Child B or C).","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"70 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants Achieving the Combined Response at the End of the Follow-up Period","description":"Combined response was defined as alanine aminotransferase (ALT) normalization plus lowering of hepatitis B virus (HBV) deoxyribo nucleic acid (DNA) levels to \\<20,000 copies/mL (\\<3,400 IU/mL) and was measured at the end of the 48-week follow-up period. Participants with missing 48 weeks follow-up measurements were considered as non-responders. However, if the scheduled 48-weeks post-treatment tests were performed earlier or later than 48 weeks post-treatment, but not earlier than 36 weeks post-treatment, the corresponding results were considered to determine response.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.8","spread":null},{"groupId":"OG001","value":"25.0","spread":null},{"groupId":"OG002","value":"20.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving the Combined Response at the End of Treatment","description":"Combined response was defined as ALT normalization plus lowering of HBV-DNA levels to \\<20,000 copies/mL (\\<3,400 IU/mL). In case of missing end of treatment measurements, the next available post-treatment value was used.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"29.4","spread":null},{"groupId":"OG001","value":"38.5","spread":null},{"groupId":"OG002","value":"32.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving the Combined Response at 24 Weeks of Follow-up","description":"Combined response was defined as ALT normalization plus lowering of HBV-DNA levels to \\<20,000 copies/mL (\\<3,400 IU/mL). In case of missing week-24 post-treatment measurements, the nearest value with respect to the schedule time point in the time window 12 weeks post treatment until study end was used.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"23.5","spread":null},{"groupId":"OG001","value":"28.8","spread":null},{"groupId":"OG002","value":"24.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving Combined Response Using a Cut-Off for HBV-DNA Levels to 2,000 IU/mL","description":"Combined response was defined here as ALT normalization plus lowering HBV-DNA levels to a cutt-off \\<2,000 IU/mL. In case of missing end of treatment measurements, the next available post-treatment value was used. In case of missing week-24 post-treatment measurements, the nearest value with respect to the schedule time point in the time window 12 weeks post treatment until study end was used. Participants with missing 48 weeks follow-up measurements were considered as non-responders. However, if the scheduled 48-weeks post-treatment tests were performed earlier or later than 48 weeks post-treatment, but not earlier than 36 weeks post-treatment, the corresponding results were considered to determine response.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"29.4","spread":null},{"groupId":"OG001","value":"38.5","spread":null},{"groupId":"OG002","value":"28.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"21.6","spread":null},{"groupId":"OG001","value":"26.9","spread":null},{"groupId":"OG002","value":"20.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.8","spread":null},{"groupId":"OG001","value":"23.1","spread":null},{"groupId":"OG002","value":"20.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving Histological Response","description":"Histological response was defined as an improvement by \\>/= 2 in the Necroinflammatory Grading and/or by an improvement by \\>/= 1 score in Fibrosis Staging according to Ishak. Necroinflammatory Grading ranges 0-14 and is the combined score for necrosis, range 0-10 and inflammation, range 0-4. The participant is scored for only one inflammatory condition. A higher score indicates worse condition. Fibrosis Staging according to Ishak ranges 0-6 and a higher score indicates greater fibrosis.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13.7","spread":null},{"groupId":"OG001","value":"5.8","spread":null},{"groupId":"OG002","value":"8.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline of Quantitative Hepatitis B Surface Antigen (HbsAg) Level at the End of Treatment","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9642.6","spread":"19756.4"},{"groupId":"OG001","value":"7229.8","spread":"6459.0"},{"groupId":"OG002","value":"8981.0","spread":"7728.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2801.1","spread":"14691.2"},{"groupId":"OG001","value":"-2282.1","spread":"6007.1"},{"groupId":"OG002","value":"-3121.2","spread":"7128.9"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Lamivudine Genotype Resistance During PEG-IFN+LAM96 Combined Therapy","description":"Lamivudine resistance mutations were assessed by detection of the following mutations: rtL80V, rtL80I, rtV173G, rtV173L, rtL180M, rtA181T, rtA181V, rtM204V, rtM204I and rtN236T.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Percentage of Participants With ALT Normalization","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"35.3","spread":null},{"groupId":"OG001","value":"40.4","spread":null},{"groupId":"OG002","value":"40.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"45.1","spread":null},{"groupId":"OG001","value":"46.2","spread":null},{"groupId":"OG002","value":"40.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"35.3","spread":null},{"groupId":"OG001","value":"34.6","spread":null},{"groupId":"OG002","value":"36.0","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Percentage of Participants With HBV-DNA Lowering to <3,400 IU/mL and to < 2,000 IU/mL","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"60.8","spread":null},{"groupId":"OG001","value":"67.3","spread":null},{"groupId":"OG002","value":"76.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"23.5","spread":null},{"groupId":"OG001","value":"30.8","spread":null},{"groupId":"OG002","value":"24.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.8","spread":null},{"groupId":"OG001","value":"30.8","spread":null},{"groupId":"OG002","value":"20.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"58.8","spread":null},{"groupId":"OG001","value":"67.3","spread":null},{"groupId":"OG002","value":"72.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"21.6","spread":null},{"groupId":"OG001","value":"28.8","spread":null},{"groupId":"OG002","value":"20.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.8","spread":null},{"groupId":"OG001","value":"28.8","spread":null},{"groupId":"OG002","value":"20.0","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Percentage of Participants With HBV-DNA Below Limit of Quantification","description":"HBV-DNA limit \\< 6 IU/mL was defined as below quantification.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17.6","spread":null},{"groupId":"OG001","value":"30.8","spread":null},{"groupId":"OG002","value":"24.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"7.7","spread":null},{"groupId":"OG002","value":"4.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.0","spread":null},{"groupId":"OG001","value":"7.7","spread":null},{"groupId":"OG002","value":"8.0","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Percentage of Participants With Loss of Hepatitis B Surface Antigen (HbsAg) and Hepatitis B Surface Antibodies (Anti-HBs) Seroconversion","description":"This outcome measure presents percentage of participants with a combined response of HBsAg \\< 5 IU/mL and anti-HBs positive. Positive anti-HBs represents antibodies produced against Hepatitis B Surface Antigen (HBsAg) and is an indication of recovery and immunity from HBV infection.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.0","spread":null},{"groupId":"OG001","value":"3.8","spread":null},{"groupId":"OG002","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"5.8","spread":null},{"groupId":"OG002","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"7.7","spread":null},{"groupId":"OG002","value":"0.0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":7,"n":50},"commonTop":["Asthenia","Pyrexia","Headache","Neutropenia","Influenza like illness"]}}}